CN101501068A - 改进的α-干扰素多肽 - Google Patents

改进的α-干扰素多肽 Download PDF

Info

Publication number
CN101501068A
CN101501068A CNA2006800222000A CN200680022200A CN101501068A CN 101501068 A CN101501068 A CN 101501068A CN A2006800222000 A CNA2006800222000 A CN A2006800222000A CN 200680022200 A CN200680022200 A CN 200680022200A CN 101501068 A CN101501068 A CN 101501068A
Authority
CN
China
Prior art keywords
seq
polypeptide
sequence
amino acid
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800222000A
Other languages
English (en)
Chinese (zh)
Inventor
马丹·M·佩邓加特
伊恩·萨斯
托马斯·布奎因
戴维·林
泰迪·陈
道格拉斯·格普蒂尔
埃米·布里迪厄-安德森
史蒂文·H·巴斯
菲利普·A·帕滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxygen Inc
Original Assignee
Maxygen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Inc filed Critical Maxygen Inc
Publication of CN101501068A publication Critical patent/CN101501068A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA2006800222000A 2005-05-18 2006-05-17 改进的α-干扰素多肽 Pending CN101501068A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68276905P 2005-05-18 2005-05-18
US60/682,769 2005-05-18

Publications (1)

Publication Number Publication Date
CN101501068A true CN101501068A (zh) 2009-08-05

Family

ID=37943260

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800222000A Pending CN101501068A (zh) 2005-05-18 2006-05-17 改进的α-干扰素多肽

Country Status (11)

Country Link
US (1) US7619067B2 (https=)
EP (1) EP1888633A4 (https=)
JP (1) JP2008545393A (https=)
KR (1) KR20080019619A (https=)
CN (1) CN101501068A (https=)
AU (1) AU2006299901A1 (https=)
BR (1) BRPI0609809A2 (https=)
CA (1) CA2607651A1 (https=)
IL (1) IL186880A0 (https=)
MX (1) MX2007014524A (https=)
WO (1) WO2007044083A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108733975A (zh) * 2018-03-29 2018-11-02 深圳裕策生物科技有限公司 基于二代测序的肿瘤克隆变异检测方法、装置和存储介质
CN115304665A (zh) * 2019-06-13 2022-11-08 江苏科技大学 鸭α干扰素及其突变体、制备方法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360011A1 (en) 1999-01-05 2000-07-13 Trustees Of Boston University Ordered gene assembly
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
WO2006053131A1 (en) 2004-11-11 2006-05-18 Modular Genetics, Inc. Ladder assembly and system for generating diversity
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
AU2007358605B8 (en) * 2007-09-04 2012-02-02 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
MX2010011145A (es) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
BRPI0910686A2 (pt) 2008-04-21 2015-09-29 Tissue Regeneration Therapeutics Inc células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos.
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
CN101921330B (zh) * 2010-06-02 2013-07-17 北京三元基因工程有限公司 重组人干扰素α1b突变体及其制备方法
PT2822575T (pt) 2012-03-03 2020-07-02 Immungene Inc Moléculas de fusão anticorpos-mutante de interferão modificadas
CA2998456A1 (en) 2015-09-15 2017-03-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
HRP20240949T1 (hr) * 2020-03-16 2024-10-25 Ilc Therapeutics Ltd Hibridni interferoni za liječenje virusnih infekcija
EP3901168A1 (en) * 2020-04-21 2021-10-27 Universität Duisburg-Essen Interferon alpha 2 variants and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
ES506955A0 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0205404B1 (en) 1985-06-11 1992-07-15 Ciba-Geigy Ag Hybrid interferons
AU660633B2 (en) 1990-10-17 1995-07-06 Amgen, Inc. Methods and compositions for the treatment of cell proliferation disorders
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
PT741577E (pt) 1994-03-07 2003-03-31 Imperial College Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
CA2359345A1 (en) 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU3725600A (en) 1999-03-02 2000-09-21 Maxygen, Inc. Surrogate orphan ligands for orphan receptors
RU2262510C9 (ru) 1999-05-19 2006-04-20 Лексиген Фармасьютикэлс Корп. Слитый белок, обладающий биологической активностью интерферона-альфа, димерный слитый белок, фармацевтическая композиция, их содержащая, молекула днк (варианты) и способ адресования интерферона-альфа в ткани печени
WO2001025438A2 (en) 1999-10-07 2001-04-12 Maxygen, Inc. Ifn-alpha homologues
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2ａ 및 2ｂ, 그리고 이들과 ＰＥＧ유도체와의 배합체
ATE337017T1 (de) 2002-11-15 2006-09-15 Hoffmann La Roche Positionelle isomeren von pegyliertem interferon alpha 2a
EP1565205A4 (en) 2002-11-18 2006-07-05 Maxygen Inc Interferon-alpha polypeptides and conjugates
CN101115769A (zh) 2004-05-19 2008-01-30 马克西根公司 干扰素-α多肽和偶联物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108733975A (zh) * 2018-03-29 2018-11-02 深圳裕策生物科技有限公司 基于二代测序的肿瘤克隆变异检测方法、装置和存储介质
CN115304665A (zh) * 2019-06-13 2022-11-08 江苏科技大学 鸭α干扰素及其突变体、制备方法和应用

Also Published As

Publication number Publication date
US20080226597A1 (en) 2008-09-18
EP1888633A4 (en) 2010-01-27
MX2007014524A (es) 2008-02-07
CA2607651A1 (en) 2007-04-19
EP1888633A2 (en) 2008-02-20
WO2007044083A2 (en) 2007-04-19
WO2007044083A3 (en) 2009-04-16
JP2008545393A (ja) 2008-12-18
KR20080019619A (ko) 2008-03-04
BRPI0609809A2 (pt) 2011-10-11
AU2006299901A1 (en) 2007-04-19
US7619067B2 (en) 2009-11-17
IL186880A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
US7541163B2 (en) Interferon-alpha polypeptides and conjugates
US7314613B2 (en) Interferon-alpha polypeptides and conjugates
CN101501068A (zh) 改进的α-干扰素多肽
US20040219131A1 (en) Interferon-alpha polypeptides and conjugates
KR20070022279A (ko) 인터페론-알파 폴리펩티드 및 컨쥬게이트

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090805